News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MOMO starting
Good morning ZMTX'ers still no stockcharts but bigcharts is showing that the pullback is healthy and another run is enevitable.........We were WAY too high above the top Bollinger Band IMO now the chart is catching up....this wide spread between the B/A is to slow us down from running too fast ....give it another day or two to stabilize and let the news come into play....gotta be something for the spike in volume and the awakening of the stock?
We shall see,
|
Followers
|
3
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
112
|
|
Created
|
06/02/07
|
Type
|
Free
|
| Moderators | |||
ZMTX
O/S: 8.6 million
Float: ~ 6-7 million
ZymeTx, Inc. is a biotechnology company engaged in the development, distribution and introduction of novel solutions for the diagnosis, treatment and surveillance of infectious viral diseases. These products include the ZstatFlu® Rapid Test for Influenza A and B, ViraStat® Parainfluenza Laboratory Test, and the National Flu Surveillance Network - NFSN®.
ZstatFlu, the world's first rapid point-of-care flu diagnostic test, was granted waived status by the U.S. Food and Drug Administration (FDA), announced Norman Proulx, president and chief executive officer of ZymeTx Inc, developer and manufacturer. http://www.pharmabiz.com/article/detnews.asp?Arch=a&articleid=6297§ionid=14
**Waived status is the fastest kind of approval granted by the FDA. This proves the effectiveness of the ZMTX product line in detecting viral outbreaks.
Rapid diagnostic testing for influenza is available in many hospital laboratories, and it can detect influenza A and B viruses. According to the package inserts for 4 commercial kits (Directigen Flu A+B, Becton Dickinson; Flu OIA, Biostar; Quick Vue, Quidel; and ZstatFlu, ZymeTx), using culture as the gold standard, the sensitivities ranged from 62% to 95% and the specificities, from 69% to 100%. Sensitivity and specificity vary with the differential detection of influenza A and B viruses, specimen type and integrity, and prevalence of disease in the population being tested. The best results are obtained from nasal aspirate specimens.
Rapid influenza testing is classified by the Clinical Laboratory Improvement Act (CLIA) as moderately complex or waived. QuickVue and ZstatFlu have waived status and can be performed in physicians' offices. Directigen Flu A+B and Flu OIA are moderately complex and therefore should be performed in hospital or reference laboratories with dedicated personnel. The processing time is 15 to 30 minutes for most commercially available tests.
http://www.medscape.com/viewarticle/431124_2
http://www.hhs.gov/pandemicflu/plan/sup2.html
CURRENT PROJECTS:
Respiratory Syncytial Virus (RSV) Program
Hepatitis C Virus (HCV) Program
Immunomodulation Therapeutics Program
ViraZyme® Technology Platform
ZstatFlu-II Diagnostic Chemiluminescent Technology Platform
ViraStat® Technology Platform
HEALTH CARE PROVIDERS DIRECT, INC. SYMBOL: HPRD.OB (.65) is the marketing arm of ZMTX.
The ZMTX products are distributed by HPRD: http://www.healthcareprovidersdirect.com/
ZMTX holds the FDA approved licenses that HPRD relies upon to market its products. HPRD and ZMTX would benefit directly from ANY outbreak of avian flu or a global flu epidemic that the ZMTX products could detect.
Recent State Advisory Recommending ZMTX Test Kits Be Used State Wide
Pennsylvania Department of Health Health Alert Network 2006
http://www.dsf.health.state.pa.us/health/cwp/view.asp?A=171&Q=246228&pp=12&n=1
